Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells

Yuzo Sato, Shiori Matsuda, Ami Maruyama, Joji Nakayama, Tomoyuki Miyashita, Hibiki Udagawa, Shigeki Umemura, Kazuyoshi Yanagihara, Atsushi Ochiai, Masaru Tomita, Tomoyoshi Soga, Katsuya Tsuchihara, Hideki Makinoshima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), and glycinamide ribonucleotide formyltransferase (GART). In order to select the most suitable patients for effective therapy with drugs targeting specific metabolic pathways, there is a need for better predictive metabolic biomarkers. Antifolates can alter global metabolic pathways in MPM cells, yet the metabolic profile of treated cells has not yet been clearly elucidated. Here we found that MPM cell lines could be categorized into two groups according to their sensitivity or resistance to pemetrexed treatment. We show that pemetrexed susceptibility could be reversed and DNA synthesis rescued in drug-treated cells by the exogenous addition of the nucleotide precursors hypoxanthine and thymidine (HT). We observed that the expression of pemetrexed-targeted enzymes in resistant MPM cells was quantitatively lower than that seen in pemetrexed-sensitive cells. Metabolomic analysis revealed that glycine and choline, which are involved in one-carbon metabolism, were altered after drug treatment in pemetrexed-sensitive but not resistant MPM cells. The addition of HT upregulated the concentration of inosine monophosphate (IMP) in pemetrexed-sensitive MPM cells, indicating that the nucleic acid biosynthesis pathway is important for predicting the efficacy of pemetrexed in MPM cells. Our data provide evidence that may link therapeutic response to the regulation of metabolism, and points to potential biomarkers for informing clinical decisions regarding the most effective therapies for patients with MPM.

Original languageEnglish
Article number1129
JournalFrontiers in Pharmacology
Volume9
Issue numberOCT
DOIs
Publication statusPublished - 2018 Oct 12

Fingerprint

Pemetrexed
Folic Acid Antagonists
Hypoxanthine
Metabolic Networks and Pathways
Thymidine
Hydroxymethyl and Formyl Transferases
Biomarkers
Pharmaceutical Preparations
Therapeutics
Inosine Monophosphate
Metabolomics
Metabolome
Malignant Mesothelioma
Enzymes
Drug Delivery Systems
Choline
Glycine
Nucleic Acids
Carbon
Nucleotides

Keywords

  • Antifolate therapy
  • Mesothelioma
  • Purine
  • Pyrimidine
  • Tumor metabolism

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sato, Y., Matsuda, S., Maruyama, A., Nakayama, J., Miyashita, T., Udagawa, H., ... Makinoshima, H. (2018). Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells. Frontiers in Pharmacology, 9(OCT), [1129]. https://doi.org/10.3389/fphar.2018.01129

Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells. / Sato, Yuzo; Matsuda, Shiori; Maruyama, Ami; Nakayama, Joji; Miyashita, Tomoyuki; Udagawa, Hibiki; Umemura, Shigeki; Yanagihara, Kazuyoshi; Ochiai, Atsushi; Tomita, Masaru; Soga, Tomoyoshi; Tsuchihara, Katsuya; Makinoshima, Hideki.

In: Frontiers in Pharmacology, Vol. 9, No. OCT, 1129, 12.10.2018.

Research output: Contribution to journalArticle

Sato, Y, Matsuda, S, Maruyama, A, Nakayama, J, Miyashita, T, Udagawa, H, Umemura, S, Yanagihara, K, Ochiai, A, Tomita, M, Soga, T, Tsuchihara, K & Makinoshima, H 2018, 'Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells', Frontiers in Pharmacology, vol. 9, no. OCT, 1129. https://doi.org/10.3389/fphar.2018.01129
Sato, Yuzo ; Matsuda, Shiori ; Maruyama, Ami ; Nakayama, Joji ; Miyashita, Tomoyuki ; Udagawa, Hibiki ; Umemura, Shigeki ; Yanagihara, Kazuyoshi ; Ochiai, Atsushi ; Tomita, Masaru ; Soga, Tomoyoshi ; Tsuchihara, Katsuya ; Makinoshima, Hideki. / Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. OCT.
@article{acb9e78e8535403398bfbffb3dd5c5e7,
title = "Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells",
abstract = "Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), and glycinamide ribonucleotide formyltransferase (GART). In order to select the most suitable patients for effective therapy with drugs targeting specific metabolic pathways, there is a need for better predictive metabolic biomarkers. Antifolates can alter global metabolic pathways in MPM cells, yet the metabolic profile of treated cells has not yet been clearly elucidated. Here we found that MPM cell lines could be categorized into two groups according to their sensitivity or resistance to pemetrexed treatment. We show that pemetrexed susceptibility could be reversed and DNA synthesis rescued in drug-treated cells by the exogenous addition of the nucleotide precursors hypoxanthine and thymidine (HT). We observed that the expression of pemetrexed-targeted enzymes in resistant MPM cells was quantitatively lower than that seen in pemetrexed-sensitive cells. Metabolomic analysis revealed that glycine and choline, which are involved in one-carbon metabolism, were altered after drug treatment in pemetrexed-sensitive but not resistant MPM cells. The addition of HT upregulated the concentration of inosine monophosphate (IMP) in pemetrexed-sensitive MPM cells, indicating that the nucleic acid biosynthesis pathway is important for predicting the efficacy of pemetrexed in MPM cells. Our data provide evidence that may link therapeutic response to the regulation of metabolism, and points to potential biomarkers for informing clinical decisions regarding the most effective therapies for patients with MPM.",
keywords = "Antifolate therapy, Mesothelioma, Purine, Pyrimidine, Tumor metabolism",
author = "Yuzo Sato and Shiori Matsuda and Ami Maruyama and Joji Nakayama and Tomoyuki Miyashita and Hibiki Udagawa and Shigeki Umemura and Kazuyoshi Yanagihara and Atsushi Ochiai and Masaru Tomita and Tomoyoshi Soga and Katsuya Tsuchihara and Hideki Makinoshima",
year = "2018",
month = "10",
day = "12",
doi = "10.3389/fphar.2018.01129",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - Metabolic characterization of antifolate responsiveness and nonresponsiveness in malignant pleural mesothelioma cells

AU - Sato, Yuzo

AU - Matsuda, Shiori

AU - Maruyama, Ami

AU - Nakayama, Joji

AU - Miyashita, Tomoyuki

AU - Udagawa, Hibiki

AU - Umemura, Shigeki

AU - Yanagihara, Kazuyoshi

AU - Ochiai, Atsushi

AU - Tomita, Masaru

AU - Soga, Tomoyoshi

AU - Tsuchihara, Katsuya

AU - Makinoshima, Hideki

PY - 2018/10/12

Y1 - 2018/10/12

N2 - Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), and glycinamide ribonucleotide formyltransferase (GART). In order to select the most suitable patients for effective therapy with drugs targeting specific metabolic pathways, there is a need for better predictive metabolic biomarkers. Antifolates can alter global metabolic pathways in MPM cells, yet the metabolic profile of treated cells has not yet been clearly elucidated. Here we found that MPM cell lines could be categorized into two groups according to their sensitivity or resistance to pemetrexed treatment. We show that pemetrexed susceptibility could be reversed and DNA synthesis rescued in drug-treated cells by the exogenous addition of the nucleotide precursors hypoxanthine and thymidine (HT). We observed that the expression of pemetrexed-targeted enzymes in resistant MPM cells was quantitatively lower than that seen in pemetrexed-sensitive cells. Metabolomic analysis revealed that glycine and choline, which are involved in one-carbon metabolism, were altered after drug treatment in pemetrexed-sensitive but not resistant MPM cells. The addition of HT upregulated the concentration of inosine monophosphate (IMP) in pemetrexed-sensitive MPM cells, indicating that the nucleic acid biosynthesis pathway is important for predicting the efficacy of pemetrexed in MPM cells. Our data provide evidence that may link therapeutic response to the regulation of metabolism, and points to potential biomarkers for informing clinical decisions regarding the most effective therapies for patients with MPM.

AB - Antifolates are a class of drugs effective for treating malignant pleural mesothelioma (MPM). The majority of antifolates inhibit enzymes involved in purine and pyrimidine synthesis such as dihydrofolate reductase (DHFR), thymidylate synthase (TYMS), and glycinamide ribonucleotide formyltransferase (GART). In order to select the most suitable patients for effective therapy with drugs targeting specific metabolic pathways, there is a need for better predictive metabolic biomarkers. Antifolates can alter global metabolic pathways in MPM cells, yet the metabolic profile of treated cells has not yet been clearly elucidated. Here we found that MPM cell lines could be categorized into two groups according to their sensitivity or resistance to pemetrexed treatment. We show that pemetrexed susceptibility could be reversed and DNA synthesis rescued in drug-treated cells by the exogenous addition of the nucleotide precursors hypoxanthine and thymidine (HT). We observed that the expression of pemetrexed-targeted enzymes in resistant MPM cells was quantitatively lower than that seen in pemetrexed-sensitive cells. Metabolomic analysis revealed that glycine and choline, which are involved in one-carbon metabolism, were altered after drug treatment in pemetrexed-sensitive but not resistant MPM cells. The addition of HT upregulated the concentration of inosine monophosphate (IMP) in pemetrexed-sensitive MPM cells, indicating that the nucleic acid biosynthesis pathway is important for predicting the efficacy of pemetrexed in MPM cells. Our data provide evidence that may link therapeutic response to the regulation of metabolism, and points to potential biomarkers for informing clinical decisions regarding the most effective therapies for patients with MPM.

KW - Antifolate therapy

KW - Mesothelioma

KW - Purine

KW - Pyrimidine

KW - Tumor metabolism

UR - http://www.scopus.com/inward/record.url?scp=85055338504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055338504&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.01129

DO - 10.3389/fphar.2018.01129

M3 - Article

AN - SCOPUS:85055338504

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - OCT

M1 - 1129

ER -